Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma · line 2 · Bortezomib + Rituximab + Dexamethasone (BDR) × 6-8 cycles — chemo-free alternative for r/r WM (incl CXCR4-WHIM-mutated)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-VRD-WM |
| ID | IND-WM-2L-VRD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-WM |
| Sources | SRC-ESMO-WM-2024 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L+ chemo-free time-limited alternative for r/r WM. UA practical advantage — all components reimbursed. Particularly preferred for CXCR4-WHIM-mut subset.
Used By
Algorithms
ALGO-WM-2L- ALGO-WM-2L